The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

  ()
Shares of NantKwest Inc. spiked as much as 85% higher, setting a new 52-week high price, after the company reported a series of positive results at the 38th JP Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were noted in as many as six different multiple tumor types when "natural killer" cells and T cells are activated simultaneously. read more >

Biotech Announces Deal with Bayer on Non-Hormonal Contraception

Research Report
  ()
Details of the arrangement and an update on the company's pipeline are provided in a Dawson James report. read more >

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

  ()
Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in four different solid tumor indications. read more >

Ultragenyx Shares Increase 30% on Results from Phase 1/2 OTC Deficiency Study

  ()
Rare disease biopharmaceutical company Ultragenyx Pharmaceutical's shares traded 30% higher after the firm reported positive topline results from Cohorts 2 and 3 in its Phase 1/2 study of DTX301 gene therapy in Ornithine Transcarbamylase Deficiency. read more >

Applied Genetic Tech's Shares Double on 6-Month X-Linked RP Study Results

  ()
Shares of Applied Genetic Technologies skyrocketed to a new 52-week high price after the company reported positive six-month data from its ongoing Phase 1/2 clinical study for treatment in X-Linked Retinitis Pigmentosa. The firm stated that the trial data suggests durable and meaningful improvements in central visual sensitivity and advised that it plans to initiate a pivotal trial by year-end 2020. read more >

Developer of Oncology Therapeutics to Have 'Catalyst Rich' 2020

Research Report
  ()
The near-term events expected to trigger movement of the biotech's share price are outlined in a ROTH Capital Partners report. read more >

Applied Therapeutics Investors Like the ACTION in Phase 2 Galactosemia Study

  ()
Applied Therapeutics' shares traded 25% higher after the company reported positive topline results from its Pivotal Phase 2 ACTION Study of AT-007 for use in the treatment of galactosemia. The firm expects to file for regulatory approval of AT-007 in H2/20. read more >

Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial

  ()
Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria. read more >

Kyorin's $175M Partnership Offers Good Life for aTyr Pharma in Japan

  ()
aTyr Pharma's shares traded 45% higher after the firm reported that it had entered into a collaboration agreement with Kyorin Pharmaceutical for development and commercialization of its ATYR1923 drug in Japan. read more >

Biopharma's Migraine Phase 3 Trial Results 'Robust,' 'Impressive'

Research Report
  ()
These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. read more >

Clinical Program Started for Agitation with Schizophrenia, Bipolar Disorder

Research Report
  ()
The design of and an opinion on the included studies are provided in an H.C. Wainwright & Co. report. read more >
News Update

Biopharma Releases Topline Results from Psoriasis Trial

News Update
  ()
The company, however, will continue to advance the same therapeutic in two other diseases. read more >

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

  ()
Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity financing from BeiGene and two other investment groups. read more >

Pulmatrix's Licensing Deal with the JNJ Lung Cancer Initiative Sends Shares Up 100%

  ()
Pulmatrix's shares opened 90% higher after the firm reported that it has signed a kinase inhibitor licensing agreement with the Lung Cancer Initiative at Johnson & Johnson. read more >

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

  ()
Shares of Savara opened nearly 140% higher after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). read more >

Iterum Therapeutics Shares Double After Completing Enrollment in Phase 3 Antibiotic Trial

  ()
Iterum Therapeutics shares traded more than 100% higher after the company reported that it has completed enrollment in its Phase 3 SURE 1 clinical study of oral sulopenem for treatment of uncomplicated urinary tract infections. The firm expects to receive topline data results in Q1/20. read more >

Biopharma Continues 'Positive Push Forward in Breast Cancer'

Research Report
  ()
The latest clinical trial results and next step are reviewed in an H.C. Wainwright & Co. report. read more >

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

  ()
Shares of Intra-Cellular Therapies opened greater than 100% higher after the company reported that the FDA approved its antipsychotic CAPLYTAŽ (lumateperone) drug for the treatment of schizophrenia in adults. read more >

Coverage Initiated on Immunotherapies Developer with 'Catalyst Rich 2020'

Research Report
  ()
The key business and investment points are presented in a ROTH Capital Partners report. read more >

NewLink Genetics Shares Shoot Higher after FDA Ebola Vaccine Approval

  ()
Shares of NewLink Genetics got a boost after the firm reported that the FDA approved its ERVEBO V920 vaccine used in the treatment of Zaire Ebola virus. read more >

Paratek Pharma Awarded $285 Million BARDA Contract to Combat Anthrax

  ()
Shares of Paratek Pharmaceuticals traded 40% higher after the firm announced it was awarded a BARDA BioShield program contract valued at up to $285 million for NUZYRA used to treat anthrax. read more >

Syros Pharma Teams Up with Global Blood Therapeutics to Fight Sickle Cell Disease

  ()
Syros Pharmaceuticals' shares rose 20% after the firm reported that it entered into a collaboration agreement with Global Blood Therapeutics for development of therapies for sickle cell disease and beta thalassemia that could result in payments to Syros as high as $315 million over three years. read more >

Biopharma 'Keeps Executing and Securing Milestones'

Research Report
  ()
The company's latest achievement and partnership potential are addressed in a ROTH Capital Partners report. read more >

Biopharma to Test Immunity Activator in Advanced Solid Cancers

Research Report
  ()
The company's plans for and approach to one of its most advanced drug candidates are discussed in an H.C. Wainwright & Co. report. read more >

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

  ()
Axsome Therapeutics shares reached a new 52-week high price after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application filing in H2/20. read more >
Showing Results: 26 to 50 of 131 Prev Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"PAT secured a CA$975K contract from Canada's defense department." ❭
– Ron Struthers, Struthers Resource Stock Report
"The development of MAG's Juanicipio continues to advance on schedule." ❭
– Heiko Ihle, H.C. Wainwright & Co., Rodman & Renshaw
"Geophysical surveying of LIO's Tuvatu identified numerous targets." ❭
– Ryan Walker, Echelon Wealth Partners
"ELY announced deals that add two important assets to its portfolio." ❭
– Gwen Preston, Resource Maven
"GSV is well positioned to participate in an M&A wave." ❭
– Adam Graf, B. Riley FBR Inc.